DHP Research is pleased to announce that the following presentation in collaboration with the University of Sheffield and Isis Innovations, University of Oxford has been accepted for the ISPOR 16th Annual European Congress, 2-6 November 2013, Dublin
OBJECTIVES: With the increasing use of patient reported outcome measures in diabetes, it is important to understand which dimensions are most relevant to clinical indicators, and are the most predictive when assessing clinical change over time. This is important as the PROM scores can help inform the development of tailored therapeutics by highlighting the psychosocial functioning and quality of life impacts of different treatments. The aim of this study is to assess the relationship between the Diabetes Health Profile (DHP-18) and diabetes specific clinical variables to investigate how the measure can be used in the assessment of the impacts of different related complications and treatments.
METHODS: The relationship between the DHP-18 and a number of variables, including diabetes specific and co-morbid health complications and length of time diagnosed were assessed. This was done cross-sectionally and longitudinally using a large dataset of Type 1 and Type 2 people with diabetes (n=1,802) collected in one United Kingdom health authority area. The analysis was carried out using Ordinary Least Squares and Logit regression.
RESULTS: The Psychological distress domain is significantly associated with eye and foot related complications, and a number of co-morbid conditions including depression. The Barriers to activity domain is significantly associated with eye and foot related complications, duration of diabetes and a range of co-morbid conditions. The Disinhibited eating domain is related to duration of diabetes and co morbid conditions such as bone and lung disease. The number of associated problems was also a key predictive variable.
CONCLUSIONS: The findings indicate that there is relationship between psychosocial functioning as measured by the DHP-18 and a range of clinical indicators. Tailored therapeutics can be used to change or reduce clinical concerns while also impacting on a patient’s psychosocial functioning and quality of life, and the DHP can be used to efficiently measure this.
Mulhern B1, Meadows K2, Churchman D3
1University of Sheffield, Sheffield, United Kingdom, 2DHP Research & Consultancy Ltd, Banbury, United Kingdom, 3University of Oxford, Oxford, United Kingdom
For more information contact: email@example.com